Open an account

Xencor

XNCR · NASDAQ

$24.94+$1.75 (+7.55%)TodayMarket closed ·
Prev close $23.19

About XNCR

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 260 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Employees
260
Headquarters
Pasadena, California
Listed
Dec 3, 2013
Sector
Health Care
Industry
Biotechnology
Website
xencor.com

XNCR key statistics

Market cap
1.59B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.36M
Volume
884.25K
Open price
$23.25
High today
$25.01
Low today
$23.25
52 Week high
$30.61
52 Week low
$10.38

Xencor (XNCR) at a glance

Xencor (XNCR) last traded at $24.94, with a market cap of 1.59B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $23.25 and $25.01. The current price is 7.3% above the day's low and 0.3% below its high.

Volume so far is 884.25K shares, below the average of 1.36M shares a day.

Over the past year Xencor has ranged from $10.38 to $30.61, and now sits 72% of the way up that range.

Xencor met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.29 per share against an estimate of -$0.8513.

The average analyst price target is $33.01, 32.4% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

75%of 8 analyst ratings say Buy
  • Buy75.0%
  • Hold25.0%
  • Sell0.0%
Price target · 14 analystsAvg $33.01
Low
$20.20
Now
$24.94
High
$48.30

XNCR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 55.9% on average.

  1. Q3 FY24: reported -$0.71 per share against an estimate of -$1.00
  2. Q4 FY24: reported -$0.62 per share against an estimate of -$0.7997
  3. Q1 FY25: reported -$0.66 per share against an estimate of -$0.6137
  4. Q2 FY25: reported -$0.41 per share against an estimate of -$0.7347
  5. Q3 FY25: reported -$0.08 per share against an estimate of -$0.7021
  6. Q4 FY25: reported -$0.09 per share against an estimate of -$0.6152
  7. Q1 FY26: reported -$1.71 per share against an estimate of -$0.7862
  8. Q2 FY26: reported -$0.29 per share against an estimate of -$0.8513

XNCR news

  • Press releaseBusiness Wire

    Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

  • Press releaseBusiness Wire

    Xencor Reports Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

  • Press releaseBusiness Wire

    Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

  • Press releasePRNewswire

    A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

  • Press releaseBusiness Wire

    The Biology Came First.

  • Press releaseBusiness Wire

    Xencor Reports First Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

Similar companies

Companies in the same industry as Xencor

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.